+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Chemical profiles and metabolite study of raw and processed Polygoni Multiflori Radix in rats by UPLC-LTQ-Orbitrap MS n spectrometry

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The raw and processed roots of Plygonum multiflorum Thunb (PM) are used to treat different diseases in clinical practice. In order to clarify the influence of processing, a comparative study of chemical substance analysis was carried out. As the xenobi-otics with a high enough exposure in target organs being considered as the potential effective or toxicity components, an in vivo study was also implemented to characterize the constitutes and metabolites, and meanwhile, the factor of compatibility with black bean were also considered. As a result, a total of 148 compounds were detected in PM extracts and more than 40 compounds were only detected in the processed products, which were probably new components produced during the steaming process. In in vivo study, 7 prototype components and 66 metabolites were detected or tentatively identified, 24 of which were reported for the first time. Our results indicated that processing greatly changed the chemical composition of PM and influenced the disposition of the compounds in vivo. To the best of our knowledge, this was the first global comparative study of raw and processed PM. These results expanded our knowledge about the influence of processing of PM and provided the essential data for further efficacy or toxicity studies.

          Related collections

          Author and article information

          Chinese Journal of Natural Medicines
          20 May 2018
          : 16
          : 5
          : 375--400
          1The 2nd Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006, China
          2Shanghai Huayu Pharmaceutical Limited Company, Shanghai 200000, China
          Author notes
          *Corresponding author: XU Wen, E-mail: freexuwen@ 123456163.com ; QIU Xiao-Hui, gxhqxh@ 123456medmail.com.cn

          ΔThese authors contributed equally to this work.

          These authors have no conflict of interest to declare.

          Copyright © 2018 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.
          Funded by: National Natural Science Foundation of China
          Award ID: 81373967
          Award ID: 81402887
          Funded by: Traditional Chinese Medicine Administration Bureau of Traditional Chinese Medicine Standardization project
          Award ID: ZYBZH-Y-SH-38
          This work was supported by National Natural Science Foundation of China (Nos. 81373967 and 81402887) and Traditional Chinese Medicine Administration Bureau of Traditional Chinese Medicine Standardization project (No. ZYBZH-Y-SH-38).


          Comment on this article